Economic evaluation of direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKAs) for stroke prevention in patients with atrial fibrillation: a systematic …
R Noviyani, S Youngkong, S Nathisuwan… - BMJ Evidence-Based …, 2022 - ebm.bmj.com
Objectives To assess cost-effectiveness of direct oral anticoagulants (DOACs) compared
with vitamin K antagonists (VKAs) for stroke prevention in atrial fibrillation (AF) by pooling …
with vitamin K antagonists (VKAs) for stroke prevention in atrial fibrillation (AF) by pooling …
Methods for economic evaluations of novel oral anticoagulants in patients with atrial fibrillation: a systematic review
Y Li, P Chen, X Wang, Q Peng, S Xu, A Ma… - Applied Health Economics …, 2024 - Springer
Background Atrial fibrillation (AF) is a severe epidemiological and public health concern
among the elderly population worldwide, with substantial economic and social burdens …
among the elderly population worldwide, with substantial economic and social burdens …
Cost‐effectiveness of anticoagulants for preventing stroke in patients with non‐valvular atrial fibrillation in mainland China
H Zhou, X Nie, M Jiang, W Dong - Journal of Clinical Pharmacy …, 2022 - Wiley Online Library
What is known and objective With the high cost, the long‐term persistence of new oral
anticoagulants (NOACs) was lower than that of warfarin in Chinese patients with non …
anticoagulants (NOACs) was lower than that of warfarin in Chinese patients with non …
Patient-guided modifications of oral anticoagulant drug intake during Ramadan fasting: a multicenter cross-sectional study
AA Batarfi, H Alenezi, A Alshehri, S Balelah… - Journal of thrombosis …, 2021 - Springer
Fasting Ramadan is known to influence patients' medication adherence. Data on patients'
behavior to oral anticoagulant (OAC) drug intake during Ramadan is missing. We aimed to …
behavior to oral anticoagulant (OAC) drug intake during Ramadan is missing. We aimed to …
Budget impact analysis of transcatheter aortic valve replacement in low, intermediate, and high-risk patients with severe aortic stenosis in Saudi Arabia
JL Carapinha, HA Al-Omar, F Alqoofi… - Journal of Medical …, 2022 - Taylor & Francis
Aims A budget impact analysis (BIA) comparing transcatheter aortic valve replacement
(TAVR) with SAPIEN 3 and surgical aortic valve replacement (SAVR) for severe …
(TAVR) with SAPIEN 3 and surgical aortic valve replacement (SAVR) for severe …
[HTML][HTML] Cost effectiveness of rivaroxaban versus warfarin among nonvalvular atrial fibrillation patients in Saudi Arabia: A Single–Center retrospective cohort study
Y AlRuthia, BQ AlOtaibi, RM AlOtaibi… - Saudi Pharmaceutical …, 2023 - Elsevier
Background Rivaroxaban is a novel oral anticoagulant (NOAC) that is commonly used for
stroke prevention among patients with atrial fibrillation (AF). However, its cost effectiveness …
stroke prevention among patients with atrial fibrillation (AF). However, its cost effectiveness …
A systematic review on economic evaluation studies of diagnostic and therapeutic interventions in the Middle East and North Africa
MA Nagi, PEN Dewi, M Thavorncharoensap… - … Health Economics and …, 2022 - Springer
Introduction Due to the increase in healthcare budget constraint, economic evaluation (EE)
evidence is increasingly required to inform resource allocation decisions. This study aimed …
evidence is increasingly required to inform resource allocation decisions. This study aimed …
Cost-effectiveness of direct oral anticoagulant vs. warfarin among atrial fibrillation patients with intermediate stroke risk
Background Several studies have shown the cost-effectiveness of direct oral anticoagulants
(DOACs), compared with warfarin, to prevent atrial fibrillation (AF) related complications …
(DOACs), compared with warfarin, to prevent atrial fibrillation (AF) related complications …
Cost‐Effectiveness and Budget Impact Analysis of Apixaban and Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Non‐Valvular Atrial …
A Tajik, A Abbasi, Z Goudarzi, A Izadi‐Moud… - Clinical …, 2024 - Wiley Online Library
Introduction This study evaluates the cost‐effectiveness of Apixaban and Rivaroxaban,
compared to Warfarin, for stroke prevention in patients with non‐valvular atrial fibrillation in …
compared to Warfarin, for stroke prevention in patients with non‐valvular atrial fibrillation in …
Methodological approaches to cost-effectiveness analysis in Saudi Arabia: what can we learn? A systematic review
F Maraiki, S Bazarbashi, P Scuffham… - MDM Policy & …, 2022 - journals.sagepub.com
Objective The recent establishment of the health technology assessment (HTA) entity in the
Kingdom of Saudi Arabia (KSA) has resulted in increased interest in economic evaluation …
Kingdom of Saudi Arabia (KSA) has resulted in increased interest in economic evaluation …